Skip to main content

Market Overview

UPDATE: Barclays Capital Downgrades NPS Pharmaceuticals After Announced Acquisition By Shire


In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham downgraded the rating on NPS Pharmaceuticals (NASDAQ: NPSP) from Overweight to Equal-Weight, and lowered the price target from $50.00 to $46.00.

In the report, Barclays Capital noted, “We are downgrading NPSP shares to Equal Weight from Overweight following the announcement Sunday that Shire is acquiring NPS for $46/sh. The all-cash deal implies a valuation of $5.2B for NPS and makes strategic sense, in our view, given the earnings potential of NPS's lead assets (Gattex and Natpara) which should be further enhanced under the Shire umbrella with the associated synergies (e.g., commercial presence in gastrointestinal disease, experience launching orphan drugs, and global footprint). Given the strategic value, the high level of synergies, and Shire's willingness to complete a deal in advance of the Natpara January 24 PDUFA date without a material adverse change clause, we see a high probability the transaction will be completed with little chance of another bidder emerging with a superior offer. Given that NPSP shares already largely reflect the proposed deal price, we are lowering our rating to Equal Weight from Overweight and our price target from $50 to $46.”

NPS Pharmaceuticals closed on Monday at $45.35.

Latest Ratings for NPSP

Jan 2015JP MorganMaintainsNeutral
Jan 2015BarclaysDowngradesOverweightEqual-weight
Jan 2015JefferiesMaintainsHold

View More Analyst Ratings for NPSP
View the Latest Analyst Ratings


Related Articles (NPSP)

View Comments and Join the Discussion!

Posted-In: Barclays Capital Geoffrey MeachamAnalyst Color Downgrades Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at